,title,source,link,date
31,Final Multivariate Analysis from the Phase 3 MAGNITUDE Study ...,PR Newswire,news.google.com/articles/CBMingJodHRwczovL3d3dy5wcm5ld3N3aXJlLmNvbS9uZXdzLXJlbGVhc2VzL2ZpbmFsLW11bHRpdmFyaWF0ZS1hbmFseXNpcy1mcm9tLXRoZS1waGFzZS0zLW1hZ25pdHVkZS1zdHVkeS1zaG93cy10cmVuZC10b3dhcmQtaW1wcm92ZW1lbnQtaW4tb3ZlcmFsbC1zdXJ2aXZhbC1pbi1wYXRpZW50cy13aXRoLW1ldGFzdGF0aWMtY2FzdHJhdGlvbi1yZXNpc3RhbnQtcHJvc3RhdGUtY2FuY2VyLXdpdGgtYnJjYS1hbHRlcmF0aW9ucy10cmVhdGVkLXdpdGgtbmlyYXBhcmliLWFuZC1hYmlyLTMwMTk2Mzc4NS5odG1s0gEA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-10-22
48,Tarlatamab active in previously treated small cell lung cancer,Healio,news.google.com/articles/CBMid2h0dHBzOi8vd3d3LmhlYWxpby5jb20vbmV3cy9oZW1hdG9sb2d5LW9uY29sb2d5LzIwMjMxMDIwL3RhcmxhdGFtYWItYWN0aXZlLWluLXByZXZpb3VzbHktdHJlYXRlZC1zbWFsbC1jZWxsLWx1bmctY2FuY2Vy0gEA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-10-21
0,GSK enters exclusive license agreement with Hansoh for HS-20089,GSK,news.google.com/articles/CBMib2h0dHBzOi8vd3d3Lmdzay5jb20vZW4tZ2IvbWVkaWEvcHJlc3MtcmVsZWFzZXMvZ3NrLWVudGVycy1leGNsdXNpdmUtbGljZW5zZS1hZ3JlZW1lbnQtd2l0aC1oYW5zb2gtZm9yLWhzLTIwMDg5L9IBAA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-10-20
18,Allergy Treatment Market: Analysis of Rising Business Opportunities ...,Digital Journal,news.google.com/articles/CBMiogJodHRwczovL3d3dy5kaWdpdGFsam91cm5hbC5jb20vcHIvbmV3cy9jb2hlcmVudC1tYXJrZXQtaW5zaWdodHMvYWxsZXJneS10cmVhdG1lbnQtbWFya2V0LWFuYWx5c2lzLW9mLXJpc2luZy1idXNpbmVzcy1vcHBvcnR1bml0aWVzLXdpdGgtcHJvbWluZW50LWludmVzdG1lbnQtcmF0aW8tYnktMjAzMC1hbGstYWJlbGxvLWFzLWFiYnZpZS1pbmMtYWxsZXJnYW4tYWxsZXJneS10aGVyYXBldXRpY3MtcGxjLWJhdXNjaC1oZWFsdGgtY29tcGFuaWVzLWluYy1hbGVtYmljLXBoYXJtYWNldXRpY2Fscy1saW1pdGVkLdIBAA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-10-20
74,ESMO 2023: key data to look out for from oncology's big players,The Pharma Letter,news.google.com/articles/CBMiZmh0dHBzOi8vd3d3LnRoZXBoYXJtYWxldHRlci5jb20vYXJ0aWNsZS9lc21vLTIwMjMta2V5LWRhdGEtdG8tbG9vay1vdXQtZm9yLWZyb20tb25jb2xvZ3ktcy1iaWctcGxheWVyc9IBAA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-10-20
58,CGG improves cartilage matrix metabolism in KOA | JIR,Dove Medical Press,news.google.com/articles/CBMigwFodHRwczovL3d3dy5kb3ZlcHJlc3MuY29tL2Nob25nZ3UtZ3JhbnVsZXMtaW1wcm92ZS1jYXJ0aWxhZ2UtbWF0cml4LW1ldGFib2xpc20taW4ta25lZS1vc3Rlb2FydGgtcGVlci1yZXZpZXdlZC1mdWxsdGV4dC1hcnRpY2xlLUpJUtIBAA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-10-20
47,Antisense Oligonucleotide (ASO) Therapeutics market is projected ...,GlobeNewswire,news.google.com/articles/CBMiswFodHRwczovL3d3dy5nbG9iZW5ld3N3aXJlLmNvbS9uZXdzLXJlbGVhc2UvMjAyMy8xMC8yMC8yNzY0MTk4LzAvZW4vQW50aXNlbnNlLU9saWdvbnVjbGVvdGlkZS1BU08tVGhlcmFwZXV0aWNzLW1hcmtldC1pcy1wcm9qZWN0ZWQtdG8tZ3Jvdy1hdC1hLUNBR1Itb2YtMTQtNS1ieS0yMDMzLVZpc2lvbmdhaW4uaHRtbNIBAA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-10-20
33,Dostarlimab Plus Chemo Continues to Demonstrate Strong Clinical ...,OncLive,news.google.com/articles/CBMid2h0dHBzOi8vd3d3Lm9uY2xpdmUuY29tL3ZpZXcvZG9zdGFybGltYWItcGx1cy1jaGVtby1jb250aW51ZXMtdG8tZGVtb25zdHJhdGUtc3Ryb25nLWNsaW5pY2FsLWVmZmljYWN5LWluLWFkdmFuY2VkLW5zY2xj0gEA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-10-20
24,Guide to Life Sciences,Global Competition Review,news.google.com/articles/CBMikQFodHRwczovL2dsb2JhbGNvbXBldGl0aW9ucmV2aWV3LmNvbS9ndWlkZS9ndWlkZS1saWZlLXNjaWVuY2VzL3NlY29uZC1lZGl0aW9uL2FydGljbGUvcmVjZW50LWRldmVsb3BtZW50cy1pbi10aGUtYW5hbHlzaXMtb2YtbGlmZS1zY2llbmNlcy1tZXJnZXJz0gEA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-10-20
27,Guide to Life Sciences,Global Competition Review,news.google.com/articles/CBMijwFodHRwczovL2dsb2JhbGNvbXBldGl0aW9ucmV2aWV3LmNvbS9ndWlkZS9ndWlkZS1saWZlLXNjaWVuY2VzL3NlY29uZC1lZGl0aW9uL2FydGljbGUvcHJhY3RpdGlvbmVycy1wZXJzcGVjdGl2ZS1jb29wZXJhdGl2ZS1hZ3JlZW1lbnRzLWluLWV1cm9wZdIBAA?hl=en-IN&gl=IN&ceid=IN%3Aen,2023-10-20
